JPWO2020132210A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132210A5 JPWO2020132210A5 JP2021535585A JP2021535585A JPWO2020132210A5 JP WO2020132210 A5 JPWO2020132210 A5 JP WO2020132210A5 JP 2021535585 A JP2021535585 A JP 2021535585A JP 2021535585 A JP2021535585 A JP 2021535585A JP WO2020132210 A5 JPWO2020132210 A5 JP WO2020132210A5
- Authority
- JP
- Japan
- Prior art keywords
- pathway inhibitor
- pharmaceutically acceptable
- acceptable salt
- medicament
- jak1 pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims description 57
- 230000037361 pathway Effects 0.000 claims description 57
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 54
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 46
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 27
- 208000010643 digestive system disease Diseases 0.000 claims description 27
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 26
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 12
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 9
- 230000036470 plasma concentration Effects 0.000 claims description 8
- 208000015943 Coeliac disease Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical group C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 claims description 5
- CEGWJIQFBNFMHQ-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile;hexanedioic acid Chemical group OC(=O)CCCCC(O)=O.C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 CEGWJIQFBNFMHQ-UHFFFAOYSA-N 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 30
- 239000012458 free base Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781877P | 2018-12-19 | 2018-12-19 | |
| US62/781,877 | 2018-12-19 | ||
| US201962854801P | 2019-05-30 | 2019-05-30 | |
| US62/854,801 | 2019-05-30 | ||
| US201962901377P | 2019-09-17 | 2019-09-17 | |
| US62/901,377 | 2019-09-17 | ||
| PCT/US2019/067418 WO2020132210A1 (en) | 2018-12-19 | 2019-12-19 | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514089A JP2022514089A (ja) | 2022-02-09 |
| JPWO2020132210A5 true JPWO2020132210A5 (enExample) | 2022-12-26 |
| JP7624922B2 JP7624922B2 (ja) | 2025-01-31 |
Family
ID=69326646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535585A Active JP7624922B2 (ja) | 2018-12-19 | 2019-12-19 | 胃腸疾患の治療のためのｊａｋ１経路阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11596632B2 (enExample) |
| EP (1) | EP3897627A1 (enExample) |
| JP (1) | JP7624922B2 (enExample) |
| KR (1) | KR20210116487A (enExample) |
| CN (1) | CN113692278A (enExample) |
| AU (1) | AU2019403304B2 (enExample) |
| CA (1) | CA3123596A1 (enExample) |
| IL (1) | IL284034A (enExample) |
| MA (1) | MA54544A (enExample) |
| MX (1) | MX2021007260A (enExample) |
| PH (1) | PH12021551455A1 (enExample) |
| SG (1) | SG11202106470TA (enExample) |
| TW (1) | TWI884142B (enExample) |
| WO (1) | WO2020132210A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| SG11202010092XA (en) | 2018-04-13 | 2020-11-27 | Incyte Corp | Biomarkers for graft-versus-host disease |
| EP3833350A4 (en) | 2018-08-10 | 2022-05-18 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| PH12021551455A1 (en) | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CA3157499A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| JP2025537191A (ja) * | 2022-11-08 | 2025-11-14 | アクラリス セラピューティクス、インク． | Ｉｔｋ介在性状態の治療のためのピロロピリミジン組成物 |
| WO2025144781A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| CN120699157B (zh) * | 2025-07-16 | 2025-12-16 | 安康市中心医院 | 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 |
| JP4188078B2 (ja) | 2000-06-28 | 2008-11-26 | スミスクライン ビーチャム ピー エル シー | 湿式粉砕法 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2011224484A1 (en) * | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| UA117572C2 (uk) | 2012-11-01 | 2018-08-27 | Інсайт Холдинґс Корпорейшн | Трициклічні конденсовані похідні тіофену як інгібітори jak |
| JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤の製造方法及びその中間体 |
| TWI719401B (zh) | 2013-05-17 | 2021-02-21 | 美商英塞特公司 | 作為jak抑制劑之聯吡唑衍生物 |
| KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
| MX2016014192A (es) | 2014-04-30 | 2017-05-01 | Incyte Corp | Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este. |
| CA3003283A1 (en) * | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
| BR112019012062A2 (pt) * | 2016-12-14 | 2019-11-12 | Progenity Inc | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos |
| WO2018111327A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of jak inhibitors at the site of gastrointestinal tract disease |
| PH12021551455A1 (en) | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
-
2019
- 2019-12-19 PH PH1/2021/551455A patent/PH12021551455A1/en unknown
- 2019-12-19 MX MX2021007260A patent/MX2021007260A/es unknown
- 2019-12-19 WO PCT/US2019/067418 patent/WO2020132210A1/en not_active Ceased
- 2019-12-19 MA MA054544A patent/MA54544A/fr unknown
- 2019-12-19 EP EP19842939.1A patent/EP3897627A1/en active Pending
- 2019-12-19 JP JP2021535585A patent/JP7624922B2/ja active Active
- 2019-12-19 US US16/720,465 patent/US11596632B2/en active Active
- 2019-12-19 CN CN201980090047.2A patent/CN113692278A/zh active Pending
- 2019-12-19 AU AU2019403304A patent/AU2019403304B2/en active Active
- 2019-12-19 TW TW108146771A patent/TWI884142B/zh active
- 2019-12-19 KR KR1020217022692A patent/KR20210116487A/ko active Pending
- 2019-12-19 CA CA3123596A patent/CA3123596A1/en active Pending
- 2019-12-19 SG SG11202106470TA patent/SG11202106470TA/en unknown
-
2021
- 2021-06-15 IL IL284034A patent/IL284034A/en unknown
-
2023
- 2023-01-31 US US18/103,662 patent/US12150943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021107454A5 (enExample) | ||
| JPWO2020132210A5 (enExample) | ||
| TWI241911B (en) | Sustained release ranolazine formulations | |
| JP6068765B2 (ja) | 薬学的複合製剤 | |
| WO2016105582A1 (en) | Compositions for ileo-jejunal drug delivery | |
| JP2008515905A5 (enExample) | ||
| NZ520780A (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
| JP2008069159A (ja) | 持続放出ラノラジン製剤 | |
| PT1123088E (pt) | Formulações farmacêuticas de libertação controlada contendo um cgmp inibidor de pde-5 | |
| JP2007091758A5 (enExample) | ||
| CN104220068A (zh) | 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 | |
| JP2001172181A (ja) | 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠 | |
| JP2023181218A (ja) | 持続放出ミドドリン塩酸塩組成物及び使用方法 | |
| CN105744930A (zh) | 包含他达拉非和氨氯地平的复合制剂 | |
| CN101257946B (zh) | 包含硝苯地平和/或尼索地平和血管紧张素ⅱ拮抗剂的活性成分组合的药物剂型 | |
| US9301957B2 (en) | Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation | |
| HK1211849A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| WO2013074432A1 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
| JPWO2023078333A5 (enExample) | ||
| KR20120120519A (ko) | 나이아신 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 포함하는 복합제제 및 그의 제조방법 | |
| GR1010345B (el) | Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων | |
| CN111655263A (zh) | 稳定的含硫胺素的药物制剂 | |
| KR20240147572A (ko) | 아질사르탄을 포함하는 고혈압 치료용 약학 조성물 | |
| JPWO2022235613A5 (enExample) | ||
| JP2009511535A (ja) | ５−（２−クロロフェニル）−１，２−ジヒドロ−７−フルオロ−８−メトキシ−３−メチル−ピラゾロ［３，４−ｂ］［１，４］ベンゾジアゼピン |